---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product comparison"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Product comparison. Topics: Deucrictibant: route, dose, and time to onset of symptom relief in RAPIDe-3; Deucrictibant: redosing and rescue medication in RAPIDe-3; Sebetralstat: route, dose, redosing, and time to beginning of symptom relief in KONFIDENT; Icatibant: route, dose, redosing, and time to symptom reduction in its placebo-controlled trial; 17 further topics. 21 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description/product-comparison"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Deucrictibant: route, dose, and time to onset of symptom relief in RAPIDe-3

> “Participants were randomly allocated in a 1:1 ratio to one of two double-blind crossover sequences to treat two attacks with a 20 mg oral deucrictibant immediate-release capsule or placebo as either deucrictibant–placebo or placebo–deucrictibant, stratified by age and use of long-term prophylaxis.”
> “Onset of symptom relief occurred significantly faster with deucrictibant than placebo, with median times of 1·28 h (95% CI 1·05 to 1·52) and more than 12 h (5·82 to >12), respectively (p<0·0001).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.14-2"></a>

### Deucrictibant: redosing and rescue medication in RAPIDe-3

> “If symptoms persisted or progressed, a second capsule of the same study drug was permitted 4 h or later after the first capsule, and conventional on-demand therapy as rescue medication was permitted 1 h or more after the second capsule for non-laryngeal attacks.”
> “A second capsule was used for 15 (17%) and 19 (22%) of 88 deucrictibant-treated attacks and 59 (67%) and 61 (69%) of 88 placebo-treated attacks within 12 h and 24 h, respectively (appendix p 26).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.14-3"></a>

### Sebetralstat: route, dose, redosing, and time to beginning of symptom relief in KONFIDENT

> “The recommended dosage of EKTERLY is one dose of 600 mg (two tablets) orally at the earliest recognition of an acute HAE attack.”
> “A second dose of 600 mg (two tablets) may be taken at least 3 hours after the first dose if response is inadequate, or if symptoms worsen or recur.”
> “The median time to beginning of symptom relief within 12 hours of first dose was 2.0 hours (95% CI: 1.5, 2.8) in patients administered EKTERLY 600 mg.”
> “Note: In the EKTERLY 600 mg group, 38% of patients administered a second dose within 12 hours.”
> “Less than 50% of placebo patients reached beginning of symptom relief within 12 hours; therefore, the median time could not be estimated.”

Source: [KalVista EKTERLY prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

### Icatibant: route, dose, redosing, and time to symptom reduction in its placebo-controlled trial

> “The recommended dose of FIRAZYR is 30 mg administered by subcutaneous (SC) injection in the abdominal area.”
> “Additional doses may be administered at intervals of at least 6 hours if response is inadequate or if symptoms recur.”
> “No more than 3 doses may be administered in any 24 hour period.”
> “The median time to 50% reduction in symptoms for patients with cutaneous or abdominal attacks treated with FIRAZYR (n=43) compared to placebo (n=45) was 2.0 hours [95% CI 1.5, 3.0] versus 19.8 hours [95% CI 6.1, 26.3], respectively (p<0.001).”
> “Across the three trials, FIRAZYR had a median time to 50% reduction from baseline symptoms ranging from 2.0 to 2.3 hours.”

Source: [Takeda FIRAZYR prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022150s016lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

### Ecallantide: route, administration setting, redosing, and outcome measures in its two trials

> “The recommended dose of KALBITOR is 30 mg (3 mL), administered subcutaneously in three 10 mg (1 mL) injections.”
> “If an attack persists, an additional dose of 30 mg may be administered within a 24 hour period.”
> “Because of the risk of anaphylaxis, KALBITOR should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and hereditary angioedema.”
> “In both trials, the effects of KALBITOR were evaluated using the Mean Symptom Complex Severity (MSCS) score and the Treatment Outcome Score (TOS).”

Source: [Takeda KALBITOR prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125277s081lbl.pdf)

<a id="topic-2.1.2.14-6"></a>

### Plasma-derived C1 esterase inhibitor: route, dose, and time to onset of relief in its placebo-controlled trial

> “Administer BERINERT at a dose of 20 International Units (IU) per kg body weight by intravenous injection.”
> “Subjects treated with 20 IU/kg body weight of BERINERT experienced a significant reduction (p=0.0016;”
> “in time to onset of relief from symptoms of an HAE attack as compared to placebo (median of 48 minutes for BERINERT 20 IU/kg body weight, as compared to a median of >4 hours for placebo).”

Source: [CSL Behring BERINERT prescribing information (2021)](https://labeling.cslbehring.com/pi/us/berinert/en/berinert-prescribing-information.pdf)

<a id="topic-2.1.2.14-7"></a>

### Recombinant C1 esterase inhibitor: route, dose, redosing, and time to beginning of relief in its placebo-controlled trial

> “The recommended dose of RUCONEST is 50 U per kg with a maximum of 4200 U to be administered as a slow intravenous injection over approximately 5 minutes.”
> “If the attack symptoms persist, an additional (second) dose can be administered at the recommended dose level.”
> “Time to Beginning of Relief of Symptoms, minutes RUCONEST 50 U/kg N=44 Placebo N=31 Median 90 152”

Source: [Pharming RUCONEST prescribing information (2020)](https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf)

<a id="topic-2.1.2.14-8"></a>

### Cross-trial comparison with sebetralstat and icatibant as stated by the RAPIDe-3 investigators

> “In an independent trial of 600 mg oral sebetralstat, onset of symptom relief, measured using the same PGI-C-based endpoint definition, was met with a median time of 1·79 h to 2·0 h (6·72 h to >12 h for placebo).”
> “Variations in trial designs and instruments used across trials for on-demand treatment of hereditary angioedema attacks prevent direct outcome comparisons.”
> “In this trial, complete attack resolution (no symptoms) measured using PGI-S was reached within a median time of 11·95 h with deucrictibant (placebo >48 h).”
> “Using the same PGI-S-based definition of complete symptom resolution, attacks treated with 600 mg sebetralstat required a median time of 24 h or longer (placebo >24 h) to reach the same outcome.”
> “In another trial, the subcutaneously administered bradykinin B2 receptor antagonist, icatibant, attained almost complete resolution of attack manifestations (defined as all VAS item scores ≤10 for three consecutive timepoints) in a median time of 8·5 h (placebo 19·4 h).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.14-9"></a>

### Redosing and rescue medication with deucrictibant and sebetralstat as stated by the RAPIDe-3 investigators

> “Treatment with deucrictibant resulted in relatively low use of second capsule (17%) and conventional on-demand therapy as rescue medication (7%) within 12 h, compared with 67% and 36% for placebo, respectively.”
> “In a phase 3 study of sebetralstat, 39·8% of attacks used a second dose of 600 mg sebetralstat (placebo 56·0%) and 8·6% used rescue medication within 12 h (placebo 25·0%).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.14-10"></a>

### Pharmacokinetics and potency of deucrictibant and icatibant as stated by the RAPIDe-3 investigators

> “Although deucrictibant and icatibant have the same mechanism of action in targeting the bradykinin B2 receptor, they exhibit distinct pharmacokinetic profiles.”
> “Deucrictibant has a mean elimination half-life of approximately 5·1 h,”
> “compared with approximately 1·5 h for icatibant.”
> “Mean plasma levels following a single 20 mg dose of deucrictibant immediate-release capsule achieved the EC85 of 13·8 ng/mL within 15–30 min of drug administration and were maintained for 8 h or longer,”
> “while the EC85 for icatibant has been estimated to be 54 ng/mL.”
> “Lastly, in-vitro assays indicate that deucrictibant is approximately 20-fold more potent than icatibant at the human bradykinin B2 receptor (recombinant or endogenously expressed).”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.14-11"></a>

### Safety relative to icatibant as stated by the RAPIDe-3 investigators

> “Overall, these findings confirm the safety profile of orally administered deucrictibant observed to date and are consistent with the clinical experience of the subcutaneous bradykinin B2 receptor antagonist, icatibant, with the exception of injection-site reactions.”

Source: [Riedl et al. (2026c)](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2826%2901296-1/fulltext)

<a id="topic-2.1.2.14-12"></a>

### Company statement: absence of head-to-head comparison with icatibant

> “However, we have not conducted a head-to-head comparison of icatibant or any other drug candidate to deucrictibant in a clinical trial.”
> “We have compared the published data for icatibant to data from our Phase 1, Phase 2 and Phase 3 randomized clinical trials (RAPIDe-1 and RAPIDe-3), and Phase 2/3 long-term extension study (RAPIDe-2) of deucrictibant IR.”
> “Accordingly, the value of comparisons to icatibant in this Annual Report may be limited because they are not derived from a head-to-head trial, and they are from trials that were conducted under different protocols at different sites and at different times.”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.14-13"></a>

### Company statement: anticipated differentiation of the immediate-release capsule

> “The availability of an immediate-release capsule formulation provides a good pharmacokinetic profile for on-demand treatment: rapid oral absorption independent of fed status resulting in almost immediate onset of action with longer expected duration of efficacy than subcutaneous injections of icatibant.”
> “Single dose resolution 83% of all attacks completely resolved with a single dose”
> “More potent inhibitor than icatibant - Lowest dosage of any oral AE-BK on-demand treatment”
> “Exposure exceeds the anticipated threshold therapeutic plasma level (EC85) in 30 minutes, with or without food”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

<a id="topic-2.1.2.14-14"></a>

### Company statement: anticipated position relative to the current standard of care

> “With the encouraging RAPIDe-3 results, combined with the trusted bradykinin B2 receptor antagonist mechanism seen in both icatibant and deucrictibant, we believe deucrictibant could become standard of care for on-demand treatment.”
> “the bradykinin B2 receptor antagonist icatibant (FIRAZYR, and available as a generic product”
> “which is currently the most widely used therapy); and the oral kallikrein inhibitor sebetralstat (EKTERLY).”

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm)

> “Due to its mechanism of action, deucrictibant is expected to outcompete bradykinin at the B2 receptor, resulting in direct modulation of bradykinin signaling, as demonstrated by the rapid and sustained symptom relief and attack resolution findings from RAPIDe-3.”

Source: [Pharvaris AAAAI 2026 press release (2026)](https://ir.pharvaris.com/news-releases/news-release-details/deucrictibant-data-supporting-potentially-differentiated-profile)

<a id="topic-2.1.2.14-15"></a>

### Indirect comparison of sebetralstat with recombinant C1 esterase inhibitor funded by KalVista

> “Based on a systematic literature review and feasibility assessment, only the pivotal trial for intravenous rhC1INH (NCT01188564) reported necessary data for a comparable primary efficacy endpoint (time to beginning of symptom relief) to enable an ITC with oral sebetralstat.”
> “The fixed-effects model found no significant differences in time to beginning of symptom relief between sebetralstat 300 mg and rhC1INH 50 IU/kg (hazard ratio [95% credible interval], 0.96 [0.42–2.15] to 1.19 [0.58–2.45]).”
> “Third, the location of on-demand treatment administration differed, with the KONFIDENT trial being the first phase 3 trial to allow patients to treat at home; the impact of this difference cannot be assessed.”
> “The study was supported by KalVista Pharmaceuticals.”

Source: [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11909897/)

<a id="topic-2.1.2.14-16"></a>

### Indirect comparison of recombinant C1 esterase inhibitor with sebetralstat funded by Pharming

> “In the primary analysis, rhC1-INH was associated with a statistically significant 4.5-fold increased likelihood of achieving complete resolution (HR 4.52; 95% CI 2.84–7.18) and a significant 82% reduction in redosing (OR 0.18; 95% CI 0.06–0.53) vs sebetralstat.”
> “All patients in the rhC1-INH trials had a severe or very severe attack at baseline based on the PGI-S scale [3, 4], whereas patients enrolled in the KONFIDENT trial had a range of baseline attack severities, with only 17.5% of patients having severe or very severe attacks at baseline [8].”
> “The rhC1-INH trials required clinic visits for assessment and treatment, resulting in delayed rhC1-INH administration (median 242 min) [3, 4], whereas the KONFIDENT trial allowed for self-administration of sebetralstat (median 41 min) [8].”
> “In these scenario analyses, the HRs for TTCR were 1.41 (95% CI 0.63–3.18) and 9.76 (95% CI 4.94–19.29).”
> “Rapid Service and Open Access fees were funded by Pharming Healthcare, Inc., Warren, NJ, USA.”

Source: [Anderson et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13290826/)

<a id="topic-2.1.2.14-17"></a>

### Methodological critique of the Pharming-funded indirect comparison

> “Unlike anchored comparisons, which preserve randomization through a common comparator, unanchored analyses require that all clinically relevant TEMs and PVs be identified, measured, and appropriately adjusted; the validity of unanchored comparisons depends critically on the assumption that no important differences remain between populations after adjustment [5].”
> “The unanchored comparison did not consider either attack severity or time to on-demand treatment, despite these variables being recognized as impacting treatment outcomes [8].”
> “This letter was funded by KalVista Pharmaceuticals.”

Source: [Hummel et al. (2026)](https://link.springer.com/article/10.1007/s12325-026-03836-5)

<a id="topic-2.1.2.14-18"></a>

### Health technology assessment appraisal of the sebetralstat indirect comparison

> “The company explained that it is difficult to do reliable ITCs for on-demand treatments for hereditary angioedema because of the heterogeneity in trial designs and definitions of endpoints.”
> “The committee concluded that the results from the ITC were uncertain and did not compare sebetralstat with Berinert, Cinryze or icatibant.”
> “No direct evidence was available for sebetralstat compared with icatibant or C1-INHs”

Source: [NICE sebetralstat draft guidance (2025)](https://www.nice.org.uk/guidance/gid-ta11334/documents/draft-guidance)

<a id="topic-2.1.2.14-19"></a>

### Cross-trial comparison caveats: guideline statement

> “Four types of ODT for HAE attacks are recognized as effective: exogenous intravenous (IV) C1-INH (plasma-derived [pdC1-INH] or recombinant [rC1-INH]), icatibant, sebetralstat, and ecallantide (Table 4).”
> “Direct comparisons among these options are limited.”
> “Adverse events are limited to headache, nevertheless, long-term data from extension studies and RWE are still lacking, precluding appropriate comparisons between this novel agent and existing first-line ODT options.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.1.2.14-20"></a>

### Cross-trial comparison caveats: infeasibility of a head-to-head trial

> “Lastly, it is recognized that the ideal comparison between therapies would be a randomized, double-blind, head-to-head clinical trial (double dummy design).”
> “However, in the context of HAE, there are multiple reasons making such an RCT infeasible, including challenges in aligning time to treatment for an oral versus an injectable treatment, and the ability to use a double-blind approach for evaluating oral versus injectable treatments, due to expected skin reactions with the latter.”

Source: [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11909897/)

> “Because no head-to-head trials have evaluated on-demand therapies for hereditary angioedema (HAE), variability in study designs and outcome definitions across clinical trials limits direct interpretation of relative efficacy, including time to complete resolution (TTCR) and the need for redosing.”

Source: [Anderson et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13290826/)

<a id="topic-2.1.2.14-21"></a>

### Oral therapies developed for prophylaxis and on-demand treatment

> “Over the past 6 years two oral therapies have been developed for HAE to include berotralstat for long term prophylaxis (LTP) and sebetralstat for on-demand therapy (ODT).”
> “Presently, deucrictibant, another oral HAE therapy, is under investigation and appears effective for LTP and ODT.”

Source: [Bui et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42635583/)

Additional sources: [Zuraw and Christiansen (2026)](https://pubmed.ncbi.nlm.nih.gov/42849490/)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
